Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2012 1
2014 1
2015 1
2016 2
2017 3
2018 2
2019 6
2021 4
2022 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Malfettone A, Cortés J; PARSIFAL Steering Committee and Trial Investigators. Llombart-Cussac A, et al. JAMA Oncol. 2021 Dec 1;7(12):1791-1799. doi: 10.1001/jamaoncol.2021.4301. JAMA Oncol. 2021. PMID: 34617955 Free PMC article. Clinical Trial.
[Episcleritis secondary to risedronate].
Viñas G, Olivé A, Holgado S, Costa J. Viñas G, et al. Med Clin (Barc). 2002 Apr 27;118(15):598-9. doi: 10.1016/s0025-7753(02)72464-0. Med Clin (Barc). 2002. PMID: 12015954 Review. Spanish. No abstract available.
Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred.
Font R, Buxó M, Ameijide A, Martínez JM, Marcos-Gragera R, Carulla M, Puigdemont M, Vilardell M, Civit S, Viñas G, Espinàs JA, Galceran J, Izquierdo Á, Borràs JM, Clèries R. Font R, et al. Among authors: vinas g. Sci Rep. 2022 May 16;12(1):8097. doi: 10.1038/s41598-022-12228-y. Sci Rep. 2022. PMID: 35577853 Free PMC article.
Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain.
Clèries R, Ameijide A, Buxó M, Vilardell M, Martínez JM, Font R, Marcos-Gragera R, Puigdemont M, Viñas G, Carulla M, Espinàs JA, Galceran J, Izquierdo Á, Borràs JM. Clèries R, et al. Among authors: vinas g. Int J Environ Res Public Health. 2022 Dec 27;20(1):405. doi: 10.3390/ijerph20010405. Int J Environ Res Public Health. 2022. PMID: 36612726 Free PMC article.
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry.
Garrigós L, Saura C, Martinez-Vila C, Zambelli A, Bower M, Pistilli B, Lambertini M, Ottaviani D, Diamantis N, Lumsden A, Pernas S, Generali D, Seguí E, Viñas G, Felip E, Sanchez A, Rizzo G, Santoro A, Cortellini A, Perone Y, Chester J, Iglesias M, Betti M, Vincenzi B, Libertini M, Mazzoni F, Zoratto F, Berardi R, Guida A, Wuerstlein R, Loizidou A, Sharkey R, Aguilar Company J, Matas M, Saggia C, Chiudinelli L, Colomba-Blameble E, Galazi M, Mukherjee U, Van Hemelrijck M, Marin M, Strina C, Prat A, Pla H, Ciruelos EM, Bertuzzi A, Del Mastro L, Porzio G, Newsom-Davis T, Ruiz I, Delany MB, Krengli M, Fotia V, Viansone A, Chopra N, Romeo M, Salazar R, Perez I, d'Avanzo F, Franchi M, Milani M, Pommeret F, Tucci M, Pedrazzoli P, Harbeck N, Ferrante D, Pinato DJ, Gennari A. Garrigós L, et al. Among authors: vinas g. Ther Adv Med Oncol. 2021 Nov 2;13:17588359211053416. doi: 10.1177/17588359211053416. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34777582 Free PMC article.
No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach.
Clèries R, Buxó M, Vilardell M, Ameijide A, Martínez JM, Font R, Marcos-Gragera R, Puigdemont M, Viñas G, Carulla M, Espinàs JA, Galceran J, Izquierdo Á, Borràs JM. Clèries R, et al. Among authors: vinas g. Int J Environ Res Public Health. 2022 Mar 18;19(6):3605. doi: 10.3390/ijerph19063605. Int J Environ Res Public Health. 2022. PMID: 35329292 Free PMC article.
Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
Palomeras S, Diaz-Lagares Á, Viñas G, Setien F, Ferreira HJ, Oliveras G, Crujeiras AB, Hernández A, Lum DH, Welm AL, Esteller M, Puig T. Palomeras S, et al. Among authors: vinas g. Breast Cancer Res. 2019 Jul 5;21(1):79. doi: 10.1186/s13058-019-1160-x. Breast Cancer Res. 2019. PMID: 31277676 Free PMC article.
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A, Palomeras S, Pedersen K, Morancho B, Pascual T, Galván P, Benítez S, Gomez-Miragaya J, Ciscar M, Jimenez M, Pernas S, Petit A, Soler-Monsó MT, Viñas G, Alsaleem M, Rakha EA, Green AR, Santamaria PG, Mulder C, Lemeer S, Arribas J, Prat A, Puig T, Gonzalez-Suarez E. Sanz-Moreno A, et al. Among authors: vinas g. Breast Cancer Res. 2021 Mar 30;23(1):42. doi: 10.1186/s13058-021-01390-2. Breast Cancer Res. 2021. PMID: 33785053 Free PMC article.
25 results